Congress Asset Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$844K Hold
3,356
0.01% 310
2026
Q1
$730K Sell
3,356
-320
-9% -$71K 0.01% 355
2025
Q4
$840K Sell
3,676
-225
-6% -$51.3K 0.01% 321
2025
Q3
$903K Sell
3,901
-1,255
-24% -$256K 0.01% 323
2025
Q2
$957K Sell
5,156
-197
-4% -$36.6K 0.01% 317
2025
Q1
$1.12M Sell
5,353
-6,975
-57% -$1.36M 0.01% 302
2024
Q4
$2.19M Sell
12,328
-84,001
-87% -$15.4M 0.01% 276
2024
Q3
$19M Sell
96,329
-547
-0.6% -$102K 0.13% 133
2024
Q2
$16.6M Buy
96,876
+137
+0.1% +$22.7K 0.12% 140
2024
Q1
$17.6M Sell
96,739
-5,500
-5% -$948K 0.13% 132
2023
Q4
$15.8M Sell
102,239
-4,984
-5% -$727K 0.12% 135
2023
Q3
$16M Buy
107,223
+2,034
+2% +$299K 0.14% 128
2023
Q2
$14.2M Buy
105,189
+328
+0.3% +$48.1K 0.12% 143
2023
Q1
$16.7M Sell
104,861
-140
-0.1% -$21.4K 0.16% 128
2022
Q4
$17M Sell
105,001
-137
-0.1% -$21K 0.17% 113
2022
Q3
$14.1M Buy
105,138
+1,311
+1% +$188K 0.15% 116
2022
Q2
$15.9M Buy
103,827
+475
+0.5% +$72.6K 0.15% 105
2022
Q1
$16.8M Buy
103,352
+238
+0.2% +$34.6K 0.14% 105
2021
Q4
$14M Buy
103,114
+1,982
+2% +$234K 0.11% 130
2021
Q3
$10.9M Buy
101,132
+2,451
+2% +$280K 0.09% 150
2021
Q2
$11.1M Buy
98,681
+2,461
+3% +$277K 0.09% 125
2021
Q1
$10.4M Buy
96,220
+2,681
+3% +$287K 0.09% 124
2020
Q4
$10M Buy
93,539
+5,008
+6% +$481K 0.09% 122
2020
Q3
$7.75M Buy
88,531
+3,075
+4% +$290K 0.08% 136
2020
Q2
$8.39M Sell
85,456
-1,002
-1% -$88.2K 0.1% 110
2020
Q1
$6.59M Buy
86,458
+17,586
+26% +$1.5M 0.1% 119
2019
Q4
$6.1M Sell
68,872
-5,075
-7% -$421K 0.07% 153
2019
Q3
$5.6M Sell
73,947
-69,940
-49% -$4.8M 0.07% 156
2019
Q2
$10.5M Buy
143,887
+3,577
+3% +$281K 0.13% 92
2019
Q1
$11.3M Buy
140,310
+15,027
+12% +$1.23M 0.15% 89
2018
Q4
$11.6M Sell
125,283
-13,678
-10% -$1.2M 0.17% 85
2018
Q3
$13.1M Sell
138,961
-151
-0.1% -$14.3K 0.17% 86
2018
Q2
$12.9M Buy
139,112
+49,956
+56% +$4.88M 0.18% 83
2018
Q1
$8.44M Sell
89,156
-275
-0.3% -$30.2K 0.12% 105
2017
Q4
$8.65M Sell
89,431
-28
-0% -$2.64K 0.13% 106
2017
Q3
$7.95M Buy
89,459
+82,577
+1,200% +$6.29M 0.12% 115
2017
Q2
$499K Hold
6,882
0.01% 225
2017
Q1
$448K Sell
6,882
-135
-2% -$8.49K 0.01% 226
2016
Q4
$439K Hold
7,017
0.01% 224
2016
Q3
$443K Sell
7,017
-373
-5% -$24.1K 0.01% 196
2016
Q2
$458K Sell
7,390
-460
-6% -$28K 0.01% 198
2016
Q1
$448K Hold
7,850
0.01% 199
2015
Q4
$465K Sell
7,850
-50
-0.6% -$2.88K 0.01% 201
2015
Q3
$430K Sell
7,900
-266
-3% -$17.3K 0.01% 189
2015
Q2
$549K Buy
8,166
+606
+8% +$39.6K 0.02% 195
2015
Q1
$443K Sell
7,560
-9,450
-56% -$571K 0.01% 196
2014
Q4
$1.11M Buy
17,010
+18
+0.1% +$1.14K 0.03% 187
2014
Q3
$981K Buy
16,992
+1,227
+8% +$68.1K 0.03% 186
2014
Q2
$890K Sell
15,765
-530
-3% -$27.8K 0.02% 190
2014
Q1
$838K Buy
16,295
+65
+0.4% +$3.29K 0.02% 192
2013
Q4
$857K Sell
16,230
-2,334
-13% -$115K 0.02% 185
2013
Q3
$830K Sell
18,564
-389
-2% -$17.2K 0.02% 183
2013
Q2
$784K Buy
+18,953
New +$829K 0.02% 179

Other funds holding ABBV

Congress Asset Management's ABBV Position: Q2 2026 in Review

Congress Asset Management held its AbbVie (ABBV) position steady in Q2 2026 at 3,356 shares worth $844K. The position accounts for 0.01% of the portfolio, ranked #310.

Congress Asset Management first reported a position in ABBV in Q2 2013 and has held it in 53 quarters since. The position peaked at $19M in Q3 2024. 1,476 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Congress Asset Management held 3,356 shares of AbbVie worth $844K as of Q2 2026.
  • Congress Asset Management left its AbbVie share count unchanged in Q2 2026.
  • AbbVie made up 0.01% of Congress Asset Management's portfolio in Q2 2026, its #310 holding.
  • Congress Asset Management first reported a position in AbbVie in Q2 2013 and has held it in 53 quarters since.
  • Congress Asset Management's AbbVie position peaked at $19M in Q3 2024.
  • 1,476 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Congress Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.